You are here

Sarecycline Phase 3 Trials Meet Endpoints for Moderate-to-Severe Acne

Developers to file NDA in second half of 2017

Two pivotal phase 3 trials of sarecycline (Allergan/Paratek) for the treatment of moderate-to-severe acne have met their 12-week primary endpoints of efficacy and safety. Sarecycline is a once-daily, oral, narrow-spectrum tetracycline-derived antibiotic with anti-inflammatory properties for the potential treatment of moderate-to-severe acne in the community setting. Based on the data, Allergan plans to file a new drug application (NDA) with the FDA in the second half of this year.

The SC1401 and SC1402 trials were designed to be replicative phase 3, randomized, multicenter, double-blind, placebo-controlled studies to evaluate the efficacy and safety of 1.5 mg/kg per day of sarecycline compared with placebo in the treatment of moderate-to-severe acne.

The primary objective was to evaluate the efficacy and safety of oral sarecycline compared with placebo in treating inflammatory acne lesions in patients with moderate-to-severe acne based on Investigators Global Assessment (IGA) scale score and inflammatory lesion counts. Patients were randomized (1:1) into two treatment groups to receive either sarecycline tablets (60 mg, 100 mg, and 150 mg, providing a dose of 1.5 mg/kg per day) or placebo once a day for 12 weeks.

Sarecycline was statistically significantly (P < 0.004) superior to placebo with respect to the primary efficacy endpoints. The most common adverse events occuring in more than 2% of patients in the sarecycline group were nausea (3.2%), nasopharyngitis (2.8%), and headache (2.8%). The rate of discontinuation due to adverse events among sarecycline-treated patients in the two studies combined was 1.4%.

Source: Allergan; March 27, 2017.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks